Fundraising Fox
/Companies
Sign in

Implicit Bioscience

Seattle, US · Delaware corporation · 1 known investors

Find your way into Implicit Bioscience

153 people in our graph share verified history with the Implicit Bioscience team — schools, employers, funds. One of them is your warm intro.

Alan Armstrongunlockedknows Marion Koster · together at Newcastle University (overlapped)
×11knows the team · via Newcastle University

Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment. The company's work is validated through peer-reviewed research in leading cardiology journals.

BiotechDeep TechMedical Devices

Founders & leadership

GRGarry Redlich
Garry RedlichCEO & MD, Co-founder
PPProf. Peter Andrews
Prof. Peter AndrewsChairman, Co-founder
JE
James Edward RottsolkExecutive
MK
Marion KosterChief Financial Officer & Company Secretary2013–2024A CPA Australia member with over 20 years of business experience across Australia and overseas, Koster has worked on financial reporting for listed and unlisted companies, financial modeling, and audit compliance.
BW
Brian William ZiegelaarExecutive

Board

DD
Daniel David SyrdalBoard director
LL
Lee Lawrence HuntsmanBoard director
NL
Norman LemayBoard director
RN
Richard Neil MarsdenBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$818.6K disclosed across 5 rounds · 2015–2020

▶$65.6KraisedSep 2020 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter Ronald AndrewsDirector
  • Ian Hector FrazerDirector
  • Marion KosterExecutive Officer
  • Peter Camac Huntley FryDirector
  • Garry Llewellyn RedlichExecutive Officer, Director
Amount sold
$65.6K
Proceeds to insiders
$156K
First sale
Aug 2020
Incorporated
Other, Australia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$367.2KraisedSep 2019 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian William ZiegelaarExecutive Officer
  • Marion KosterExecutive Officer
  • Peter Camac Huntley FryDirector
  • Ian Hector FrazerDirector
  • Peter Ronald AndrewsDirector
  • Garry Llewellyn RedlichExecutive Officer, Director
Amount sold
$367.2K
Proceeds to insiders
$230K
First sale
Sep 2019
Incorporated
Other, Australia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedSep 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian William ZiegelaarExecutive Officer
  • Ian Hector FrazerDirector
  • Richard Neil MarsdenDirector
  • Marion KosterExecutive Officer
  • Garry Llewellyn RedlichExecutive Officer, Director
  • Peter Ronald AndrewsDirector
Offering amount
$1.6M
Amount sold
$125K
Minimum investment
$19.3K
Proceeds to insiders
$120K
First sale
Sep 2017
Incorporated
Other, Australia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$210.1KraisedSep 2016 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel David SyrdalDirector
  • Brian William ZiegelaarExecutive Officer
  • Marion KosterExecutive Officer
  • Garry Llewellyn RedlichExecutive Officer, Director
  • Peter Ronald AndrewsDirector
  • Richard Neil MarsdenDirector
Offering amount
$750K
Amount sold
$210.1K
Proceeds to insiders
$120K
First sale
Sep 2016
Incorporated
Other, Australia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50.8KraisedNov 2015 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James Edward RottsolkExecutive Officer, Director
  • Marion KosterExecutive Officer
  • Daniel David SyrdalDirector
  • Lee Lawrence HuntsmanDirector
  • Norman LemayDirector
  • Garry Llewellyn RedlichExecutive Officer, Director
Offering amount
$7M
Amount sold
$50.8K
Minimum investment
$1
Finders' fees
$14K
Proceeds to insiders
$108K
Placement agents
RB Milestone Group LLC
First sale
Sep 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Implicit Bioscience do?
Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment. The company's work is validated through peer-reviewed research in leading cardiology journals.
Who founded Implicit Bioscience?
Implicit Bioscience was founded by Garry Redlich, Prof. Peter Andrews.
Who are Implicit Bioscience's investors?
Implicit Bioscience's investors include OphthaFund.
How much funding has Implicit Bioscience raised?
Implicit Bioscience has disclosed $818.6K raised across 5 rounds.
Where is Implicit Bioscience headquartered?
Implicit Bioscience is headquartered in Seattle, US.